In this issue:
Omitting regional nodal RT after response to neoadjuvant chemotherapy
Cost effectiveness of abemaciclib + endocrine therapy in early high-risk breast cancer
Survival after risk-reducing surgeries in young BRCA carriers with breast cancer
Selective elimination of breast surgery for invasive breast cancer
Conditional PFS after ribociclib + endocrine therapy for metastatic breast cancer
Cardioprotection in anthracycline-treated breast cancer
Omission of axillary dissection after neoadjuvant treatment
Atezolizumab + cobimetinib or idasanutlin in metastatic oestrogen receptor-positive breast cancer
Personalised mutation tracking in ctDNA for predicting breast cancer recurrence
Paclitaxel vs. docetaxel with dual HER2 blockade for HER2+ breast cancer
Please login below to download this issue (PDF)